Table 46Botulinum toxin type A (Botox) (pre vs post treatment) Quality of life - Clinical study characteristics and clinical summary of findings

No. of studiesDesignTreatment (n)Control (n)ResultsLimitationsInconsistencyIndirectnessImprecisionOther considerationsQuality
Outcome: Quality of life
1 [A]Prospective observational studyBotulinum toxin type A
(Botox)

N=42 200 U
N=32 300 U
Baseline

N=42 200 U
N=32 300 U
Incontinence-Specific Quality of Life, total summary score (lower the score the better) 200 U Baseline 34.6 (20.7) vs Week 6 21.2 (25.3) 300 U Baseline 36.6 (21.6) vs Week 6 20.2 (30.4)S (i)NNN (i)NVery low
1 [B]Prospective observational studyBotulinum toxin type A (Botox)
N=17
Mean no. of injections 7.2 (SD 1.3)
Baseline

N=17
Higher the score the better)
mean (SD)
Baseline 22.4 (18.6)
vs 4 mths 77.7 (20.9)
vs 12 mths 85.7 (16.8)
vs 24 mths 83.5 (22.1)
vs 36 mths 80.6 (15.4)
vs 72 mths 83.9 (17);
S (i)NNN(ii)NVery low
1 [C]Prospective observational studyBotulinum toxin type A (Botox)
N=137
1 to 6 injections
Baseline

N=137
Urogenital Distress Inventory (UDI)
UDI (lower the score the better)
mean (SD)
before vs after
1st injection 61.8 (1.4) 1 vs 23.0 (1.7)
2nd injection 55.5 (2.2) vs 24.0 (2.3)
3rd injection 56.4 (3.4) vs 8.6 (1.6)
4th injection 57.2 (5.0) vs 19.8 (3.6)
5th injection 54.6 (5.8) vs 8.6 (4.0)
6th injection 67 (3.4) vs 12.2 (7.5)
Similar results reported for Incontinence Impact Questionnaire (IIQ)
S (ii)NNN (ii)NVery low
1 [D]Prospecitve observational studyBotulinum toxin type A (Botox)
N=33
4 injections (1 every 6 mths)
Baseline

N=33
Quality of life index
Mean (SD) (higher the score the better) p<0.05 for all comparisons

Baseline vs 6 mths vs 12 mths vs 18 mths vs 24 mths

207.1 (111) vs 306.4 (186) vs 376.9 (180) vs 369.7 (129) vs 411.7 (32.9)
S (ii)NNN (ii)NVery low

S serious N none SD standard deviation

i

Before vs after data

ii

Data at high risk of bias (very low quality), imprecision not assessed

[A]

Cruz et al (2011) 63

[B]

Giannantoni et al (2009) 73

[C]

Khan et al (2011) 69

[D]

Kuo et al (2011) 74

From: 8, Treatment to improve bladder storage

Cover of Urinary Incontinence in Neurological Disease
Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.
NICE Clinical Guidelines, No. 148.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.